id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-341472-29opvzrj	Curley, Gerard F.	Future therapies for ARDS	2014-12-04		.txt	text/plain	1547	90	39	authors: Curley, Gerard F.; Laffey, John G. Despite more than 150 randomized clinical trials (RCTs) of multiple potential therapies, the only interventions for acute respiratory distress syndrome (ARDS) that reduce mortality are those that minimize ventilator-induced lung injury [1] . In pre-clinical studies, heparin has been found to reduce alveolar fibrin deposition and exert anti-inflammatory effects. Interferon beta (IFN-b) increases endothelial expression of CD73, the rate-limiting enzyme in the conversion of adenosine monophosphate to adenosine, which in turn binds to pulmonary A2B receptors and exerts multiple protective effects in pre-clinical models. A randomized clinical trial of hydroxymethylglutarylcoenzyme a reductase inhibition for acute lung injury (The HARP Study) The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study	./cache/cord-341472-29opvzrj.txt	./txt/cord-341472-29opvzrj.txt